Duchenne Muscular Dystrophy Drugs Market Report 2026

Duchenne Muscular Dystrophy Drugs Market Overview

• Duchenne Muscular Dystrophy Drugs market size has reached to $3.2 billion in 2025 • Expected to grow to $6.01 billion in 2030 at a compound annual growth rate (CAGR) of 13.4% • Growth Driver: Growth In Personalized Medicine Fuelling The Growth Of The Market Due To Advancements In Genomic Technologies • Market Trend: Corticosteroids In Duchenne Muscular Dystrophy Treatment Enhancing Muscle Strength And Slowing Disease Progression • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Duchenne Muscular Dystrophy Drugs Market?

Duchenne muscular dystrophy (DMD) drugs refer to medications and therapies aimed at managing and slowing the progression of Duchenne muscular dystrophy, a genetic disorder that causes muscle weakness and degeneration. These drugs work by targeting the underlying genetic mutations, improving muscle function, and enhancing quality of life. The main aim of these drugs is to preserve muscle strength, delay disease progression, and increase mobility in patients with Duchenne muscular dystrophy. The main types of drugs in the Duchenne muscular dystrophy drugs market are exon skipping drugs, corticosteroids, gene therapy, and others. Exon skipping drugs refer to specialized therapies that help the body produce a functional, although shorter, version of the dystrophin protein by skipping over faulty sections of the dystrophin gene during the protein-making process. The various routes of administration include oral and injectable, and several distribution channels including hospital pharmacies, retail pharmacies, and online pharmacies.

What Is The Duchenne Muscular Dystrophy Drugs Market Growth Forecast?

The duchenne muscular dystrophy drugs market size is expected to see rapid growth in the next few years. It will grow to $6.01 billion in 2030 at a compound annual growth rate (CAGR) of 13.4%. The growth in the forecast period can be attributed to advancements in exon skipping drugs, innovations in gene editing technologies, increasing government and regulatory support, rising investment in rare disease therapies, expansion of specialty care and hospital networks. Major trends in the forecast period include rising adoption of exon skipping therapies, increasing use of gene therapy approaches for dmd, growing preference for injectable and targeted drug delivery, expansion of online and hospital pharmacy distribution channels, development of supportive therapies such as myostatin inhibitors and utrophin modulators.

Global Duchenne Muscular Dystrophy Drugs Market Segmentation

1) By Drug Type: Exon Skipping Drugs, Corticosteroids, Gene Therapy, Other Drug Types 2) By Route Of Administration: Oral, Injectable 3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies Subsegments: 1) By Exon Skipping Drugs: Eteplirsen, Golodirsen, Viltolarsen, Casimersen, Other Exon Skipping Therapies 2) By Corticosteroids: Prednisone, Deflazacort, Other Corticosteroids 3) By Gene Therapy: Micro-dystrophin Gene Therapy, CRISPR/Cas9-Based Gene Editing, Stem Cell-Based Gene Therapy, Other Gene Therapies 4) By Other Drug Types: Utrophin Modulators, Anti-Inflammatory Agents, Antisense Oligonucleotides, Myostatin Inhibitors, Other Supportive Therapies

What Is The Driver Of The Duchenne Muscular Dystrophy Drugs Market?

The growth in personalized medicine is expected to propel the growth of the Duchenne muscular dystrophy (DMD) drugs market going forward. Personalized medicine is a medical approach that involves tailoring treatments to individual patients based on their genetic, environmental, and lifestyle factors to optimize outcomes and improve care. The demand for personalized medicine is increasing due to advancements in genomic technologies, which enable precise identification of genetic variations and tailored treatments for individuals. Personalized medicine aids Duchenne muscular dystrophy (DMD) drugs by offering targeted therapies tailored to individual genetic profiles, making treatments more effective for patients. It enhances drug development by focusing on specific genetic mutations, improving treatment outcomes and overall patient care. For instance, in February 2024, according to the Personalized Medicine Coalition (PMC), a US-based nonprofit organization, the U.S. Food and Drug Administration (FDA) approved 26 new personalized medicines in 2023, a significant increase from the 12 approved in 2022. Therefore, the growth in personalized medicine drives the Duchenne muscular dystrophy (DMD) drugs market.

Key Players In The Global Duchenne Muscular Dystrophy Drugs Market

Major companies operating in the duchenne muscular dystrophy drugs market are Pfizer Inc, Sanofi S.A, Novartis AG, Italfarmaco S.p.A, Sarepta Therapeutics Inc, PTC Therapeutics Inc, FibroGen Inc, Wave Life Sciences Ltd, Solid Biosciences Inc, NS Pharma, Capricor Therapeutics Inc, Santhera Pharmaceuticals, ReveraGen BioPharma, Antisense Therapeutics Limited, Catalyst Pharmaceuticals Inc, EspeRare Foundation, Cure Rare Disease, Akashi Therapeutics Inc, BioMarin Pharmaceutical Inc, Daiichi Sankyo Co Ltd, Nippon Shinyaku Co Ltd, Regenxbio Inc, Ultragenyx Pharmaceutical Inc, Dyne Therapeutics Inc, Entrada Therapeutics Inc.

Global Duchenne Muscular Dystrophy Drugs Market Trends and Insights

Major companies operating in the Duchenne muscular dystrophy (DMD) drugs market are focusing on developing innovative solutions, such as corticosteroids, to improve muscle strength, slow disease progression, and enhance overall patient outcomes. Corticosteroids are a class of steroid hormones produced naturally in the adrenal glands or synthesized as medications to reduce inflammation and suppress the immune system. For instance, in March 2024, Catalyst Pharmaceuticals, a US-based biopharmaceutical company, launched AGAMREE (vamorolone) oral suspension 40 mg/mL, a Food and Drug Administration (FDA)-approved treatment for Duchenne muscular dystrophy in patients aged two and older. AGAMREE is a corticosteroid that works by reducing inflammation and stabilizing muscle cell membranes, helping to slow disease progression.

What Are Latest Mergers And Acquisitions In The Duchenne Muscular Dystrophy Drugs Market?

In July 2023, Catalyst Pharmaceuticals, a US-based biopharmaceutical company, acquired an exclusive North American license for vamorolone (AGAMREE), a Duchenne Muscular Dystrophy (DMD) drug, from Santhera Pharmaceuticals for an undisclosed amount. With this acquisition, Catalyst Pharmaceuticals aims to expand its portfolio by offering a more effective alternative for Duchenne muscular dystrophy patients, and meet the growing demand for safer and more targeted treatments for Duchenne muscular dystrophy. Santhera Pharmaceuticals is a Switzerland-based pharmaceutical company specializing in developing innovative therapies for Duchenne muscular dystrophy.

Regional Outlook

North America was the largest region in the duchenne muscular dystrophy (DMD) drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain

What Defines the Duchenne Muscular Dystrophy Drugs Market?

The Duchenne muscular dystrophy (DMD) drugs market consists of sales of utrophin modulators, anti-inflammatory agents and myostatin inhibitors. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.